Literature DB >> 11816262

Correlation between activated clotting time and activated partial thromboplastin times.

Maureen A Smythe1, John M Koerber, Sandra N Nowak, Joan C Mattson, Robert L Begle, Susan J Westley, Mamtha Balasubramaniam.   

Abstract

OBJECTIVE: To evaluate the correlation between clotting time tests and heparin concentration, the correlation between activated clotting time (ACT) and activated partial thromboplastin time (aPTT) results, and to compare the clinical decisions based on ACT results with those based on aPTT results.
METHODS: Retrospective evaluation of a large database containing heparin concentrations, ACT results (1 device), and aPTT results (3 different instruments: 2 bedside, 1 laboratory-based). Correlations between heparin concentrations and clotting time tests and between ACT results and aPTT results were determined. Clinical decisions regarding heparin dosage adjustments based on ACT results were compared with those based on aPTT results.
RESULTS: Correlations between clotting time tests and heparin concentrations were r = 0.72 for ACT and r = 0.74-0.86 for the aPTT instruments. The laboratory-based aPTT had the highest correlation to heparin concentrations. The correlation between ACT and aPTT results ranged from r = 0.64-0.67. Heparin dosage adjustment decisions based on ACT results agreed with decisions based on aPTT results 59-63% of the time.
CONCLUSIONS: The laboratory-based aPTT has a stronger correlation to heparin concentration than the bedside-based aPTT and ACT. The correlation between ACT and aPTT was similar among 3 different aPTT instruments. Decisions to adjust heparin therapy based on ACT results differed from decisions based on aPTT results more than one-third of the time.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11816262     DOI: 10.1345/aph.1A141

Source DB:  PubMed          Journal:  Ann Pharmacother        ISSN: 1060-0280            Impact factor:   3.154


  7 in total

1.  Anticoagulant therapy for recurrent in-stent thrombosis following carotid artery stenting: A case report.

Authors:  Akinori Miyakoshi; Hiroki Toda; Makoto Hayase; Takeshi Kawauchi; Yuki Oichi; Etsuko Hattori
Journal:  Interv Neuroradiol       Date:  2017-06-21       Impact factor: 1.610

2.  Opposite effects of Agrimonia pilosa Ledeb aqueous extracts on blood coagulation function.

Authors:  Xianming Fei; Wufeng Yuan; Lei Jiang; Huan Wang
Journal:  Ann Transl Med       Date:  2017-04

3.  Accuracy of point-of-care coagulation testing during cardiopulmonary bypass in a patient post COVID-19 infection.

Authors:  Nimrat Grewal; David Yousef; Meindert Palmen; Robert Klautz; Jeroen Eikenboom; Jeroen Wink
Journal:  J Cardiothorac Surg       Date:  2022-05-07       Impact factor: 1.522

4.  Comparison of routine laboratory measures of heparin anticoagulation for neonates on extracorporeal membrane oxygenation.

Authors:  Jason P Sulkowski; Thomas J Preston; Jennifer N Cooper; Victoria L Duffy; Katherine J Deans; Louis G Chicoine; Peter C Minneci
Journal:  J Extra Corpor Technol       Date:  2014-03

5.  Anticoagulation Management during First Five Days of Infant-Pediatric Extracorporeal Life Support.

Authors:  Kirk R Bingham; Jeffrey B Riley; Gregory J Schears
Journal:  J Extra Corpor Technol       Date:  2018-03

6.  Activated Clotting Time as a Marker of Inflammation in Hospitalized Patients.

Authors:  Christos Papageorgiou; Andreas Synetos; Konstantinos Tampakis; Hector Anninos; Christos Kontogiannis; Alkistis Kapelouzou; Ioannis Kanakakis; Dimitrios Tousoulis; Ioannis Paraskevaidis; Konstantinos Toutouzas
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

7.  Influence of chronic kidney disease on anticoagulation levels and bleeding after primary percutaneous coronary intervention in patients treated with unfractionated heparin.

Authors:  Wouter J Kikkert; Peter M van Brussel; Peter Damman; Bimmer E Claessen; Jan P van Straalen; Marije M Vis; Jan Baan; Karel T Koch; Ron J Peters; Robbert J de Winter; Jan J Piek; Jan G P Tijssen; Jose P S Henriques
Journal:  J Thromb Thrombolysis       Date:  2016-04       Impact factor: 2.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.